References
- Obermüller N, Geiger H, Weipert C, et al. Current developments in early diagnosis of acute kidney injury. Int Urol Nephrol 2014;46:1–7
- Tofik R, Ohlsson S, Bakoush O. Urinary concentration of monocyte chemoattractant protein-1 in idiopathic glomerulonephritis: a long-term follow-up study. PLoS One 2014;9:e87857
- Ma FY, Tesch GH, Nikolic-Paterson DJ. ASK1/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney. Am J Physiol-Renal Physiol 2014;307:F1263–73
- Karbowska A, Boratynska M, Kusztal M, et al. Hypemricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients. Transplant Proc 2009;41:3052–5
- Roncal CA, Mu W, Cmker B, et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2007;292:116–22
- Kosugi T, Nakayama T, Heinig M, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol 2009;297:481–8
- Crittenden DB, Pillinger MH. New therapies for gout. Annu Rev Med 2013;64:325–37
- Csik Y, Marko BL, Mohas M, et al. The pleiotmpic effects of losartan-the importance of decreasing uric acid level. Lege Artis Med 2008;18:663–6
- Rovin BH, Doe N, Tan LC. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 1996;27:640–6
- Lepenies J, Eardley KS, Kienitz T, et al. Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-beta in patients with chronic kidney disease. Nephron Clin Pract 2011;119:c97–104
- Wu CC, Chen JS, Lu KC, et al. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta 2010;411:700–4
- Furuichi K, Wada T, Iwata Y, et al. Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia–reperfusion injury. J Am Soc Nephrol 2003;14:1066–71
- Kulkarni O, Pawar RD, Purschke W, et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007;18:2350–8
- Lee EY, Chung CH, Khoury CC, et al. The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol 2009;297:85–94
- Alique M, Sánchez-López E, Rayego-Mateos S, et al. Angiotensin II, via angiotensin receptor type 1/nuclear factor-κB activation, causes a synergistic effect on interleukin-1-β-induced inflammatory responses in cultured mesangial cells. J Renin–Angiotensin–Aldosterone Syst 2014(0):1–10.DOI: 10.1177/1470320314551564. [Epub ahead of print]. 1470320314551564
- Reid JL. Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension. J Renin–Angiotensin–Aldostemne Syst 2005;6:15–24
- Yu SY, Qi R. Role of bad in podocyte apoptosis induced by puromycin aminonucleoside. Transplant Proc 2013;45:569–73
- Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005;67:799–812
- Yu M, Ren Q, Yu SY. Role of nephrin phosphorylation inducted by dexamethasone and angiotensin II in podocytes. Mol Biol Rep 2014;41:3591–5
- Shengyou Y. Role of nephrin in podocyte injury induced by angiotensin II. J Recept Signal Transduct Res 2014(0): 1–5. [Epub ahead of print]